Daily Medication Pearl: Cangrelor (Kengreal)

Cangrelor (Kengreal) is indicated as an adjunct to percutaneous coronary intervention for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis.

Medication Pearl of the Day: Cangrelor (Kengreal)

Indication: Cangrelor (Kengreal) is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Insight:

  • Dosing: Administer 30 mcg/kg intravenous (IV) bolus prior to PCI followed immediately by a 4 mcg/kg/min IV infusion for at least 2 hours or duration of procedure, whichever is longer.
  • Dosage forms: Single-use 10 mL vial containing 50 mg cangrelor as a lyophilized powder for reconstitution.
  • Adverse events: The most common adverse reaction is bleeding.
  • Mechanism of action: Cangrelor is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation.

Source: Kengreal Full Prescribing Information (chiesiusa.com)